Researchers reported an experimental molecule that “reprograms” the brain’s immune cells in a way that could restore protective functions against Alzheimer’s disease. The work, led by José Vicente Sánchez Mut of the Institute for Neurosciences (CSIC and Miguel Hernández University), frames microglial immune dysfunction as a lever for slowing neurodegeneration. If the approach translates beyond preclinical findings, it could represent a shift from simply suppressing neuroinflammation to actively modulating immune-cell state. It also aligns with broader efforts in Alzheimer’s to target neuroimmune pathways tied to disease progression. The report adds another candidate direction as companies and academic groups explore how to engineer or trigger immune phenotypes inside the central nervous system.